Incidence of SARS-CoV-2 infection among healthcare workers before and after COVID-19 vaccination in a tertiary paediatric hospital in Warsaw
Description
Conceptual proposition: to identify factors associated with HCW SARS-CoV-2 infection which make it possible to direct the management of health care services. Research objective: to analyse the incidence of new SARS-CoV-2 infection among HCWs (before and after vaccination with BNT162b2) and to explore demographic and occupational factors associated with SARS-CoV-2 infection. To analyse the vaccine effectiveness against any SARS-CoV-2 infection in HCWs. Collected data: age, gender, profession, workplace, vaccination status, voluntary SARS-CoV-2 nucleocapsid antibody test results (performed before implementation of the HCW vaccination programme in January 2021), SARS-CoV-2 RNA results from longitudinal universal screening (between October 20, 2020, and May 6, 2021, which correspond to epidemiological (epi) week 43, 2020 and epi week 18, 2021, a period covering the second and third epidemic waves in Poland), and SARS-CoV-2 RNA results from contact tracing, symptomatic testing, or testing upon return to work after sick leave (due to respiratory illness) collected from October 20, 2020, up to August 31, 2021 (epi week 43, 2020 to epi week 35, 2021).
Files
Steps to reproduce
The database aggregates data from multiple sources. In particular, the following data were extracted directly from the prospectively maintained laboratory records: demographic (age and gender); results of the SARS-CoV-2 RNA RT-PCR test from longitudinal universal screening (between October 20, 2020, and May 6, 2021, which corresponds to epidemiological (epi) week 43, 2020 and epi week 18, 2021, the period covering the second and third epidemic waves in Poland); SARS-CoV-2 RNA results from contact tracing, symptomatic testing or testing upon return to work after sick leave (due to respiratory illness) collected from October 20, 2020, up to August 31, 2021 (epi week 43, 2020, to epi week 35, 2021); IgG antibodies to the nucleocapsid protein of SARS-CoV-2 (if available).